Cargando…
Feasibility and Optimal Time Point of [(68)Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
BACKGROUND: Prostate-specific membrane antigen (PSMA) targeted molecular imaging using positron emission tomography (PET) has significantly improved the diagnosis and treatment of prostate cancer (PCA). OBJECTIVE: To assess the feasibility and compare the diagnostic accuracy of [(68)Ga]Ga-PSMA-11 PE...
Autores principales: | Huebner, Nicolai, Rasul, Sazan, Baltzer, Pascal, Clauser, Paola, Hermann Grubmüller, Karl, Mitterhauser, Markus, Hacker, Marcus, Heidenreich, Axel, Rajwa, Pawel, Fajkovic, Harun, Shariat, Shahrokh F., Grubmüller, Bernhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142741/ https://www.ncbi.nlm.nih.gov/pubmed/35638090 http://dx.doi.org/10.1016/j.euros.2022.04.003 |
Ejemplares similares
-
Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2023) -
Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media?
por: Huebner, Nicolai Alexander, et al.
Publicado: (2020) -
Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
por: Rasul, Sazan, et al.
Publicado: (2019) -
The current role of precision surgery in oligometastatic prostate cancer
por: von Deimling, M., et al.
Publicado: (2022) -
Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
por: Rasul, Sazan, et al.
Publicado: (2020)